Top Markets
Coin of the day
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Rangering i aksjer #39036
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Aksjekurs
$0.38
Sist synkronisert: 2023-09-01
Markedsverdi
$677.16K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Aceragen, Inc. (ACGN)

Kategori

Aksjeprishistorikk for Aceragen, Inc. (ACGN)
Høyeste sluttskurs: $0.38 den 2023-09-01

Laveste sluttskurs: $64.33K den 1996-01-01
Aksjeprishistorikk for Aceragen, Inc. fra 1996 til 2026
Årlig aksjeprisytelse
År Ytelse
2023 -92.15%
2022 -56.36%
2021 -85.30%
2020 156.42%
2019 -62.29%
2018 -71.51%
2017 25.28%
2016 -54.63%
2015 -10.86%
2014 28.19%
2013 290.03%
2012 -27.35%
2011 -57.65%
2010 -48.14%
2009 -35.84%
2008 -34.66%
2007 126.13%
2006 11.76%
2005 25.16%
2004 -60.39%
2003 51.06%
2002 -54.68%
2001 218.06%
2000 -48.13%
1999 -40.76%
1998 -61.27%
1997 -85.90%
1996 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$506.54 29.78%
US
$843.80 29.33%
NL
$729.87 6.86%
CH
$1.07K -6.40%
KR
$252.41 11.51%
BE